{"id":76994,"date":"2018-06-06T07:48:35","date_gmt":"2018-06-06T07:48:35","guid":{"rendered":"https:\/\/essays.homeworkacetutors.com\/overview-of-ocular-histoplasmosis-syndrome-ohs\/"},"modified":"2018-06-06T07:48:35","modified_gmt":"2018-06-06T07:48:35","slug":"overview-of-ocular-histoplasmosis-syndrome-ohs","status":"publish","type":"post","link":"https:\/\/www.colapapers.com\/us\/overview-of-ocular-histoplasmosis-syndrome-ohs\/","title":{"rendered":"Overview of Ocular Histoplasmosis Syndrome (OHS)"},"content":{"rendered":"<div class=\"content position-relative mb-4\">\n<p><del><strong>Dr Pradeep Venkatesh<\/strong><\/del><\/p>\n<p><strong>Histoplasmosis<\/strong><\/p>\n<p>Amol D Kulkarni and Suresh R Chandra<\/p>\n<p><del><ins><\/ins><\/del><strong>Introduction<\/strong><\/p>\n<p><del><\/del>Histoplasmosis is a systemic disease caused by <em>Histoplasma capsulatum<\/em>.<del><sup>1<\/sup><\/del><ins><\/ins><\/p>\n<p><del><ins><\/ins><\/del><strong>Introduction<\/strong><\/p>\n<p><del><\/del>Histoplasmosis is a systemic disease caused by <em>Histoplasma capsulatum<\/em>.<del><sup>1<\/sup><\/del><ins> <\/ins>It produces intracellular granulomatous inflammation of many organs including eyes, lungs, liver, spleen<ins>,<\/ins> etc.<del> <\/del> Ocular histoplasmosis<ins> <\/ins>syndrome (OHS) is characterized by a triad of signs <ins>\u2013<\/ins><del>of<\/del><ins> <\/ins>punched-out atrophic choroidal scars in the macula or periphery, peripapillary atrophy and choroidal<ins> <\/ins>neovascular membrane (CNVM).<del><sup>2<\/sup><\/del><\/p>\n<p><del><ins><\/ins><\/del><del><strong>Etiology-<\/strong><\/del><ins><strong>Ae<\/strong><\/ins><ins><strong>tiology<\/strong><\/ins><\/p>\n<p><del><ins><\/ins><\/del><del><em>Histoplasmacapsulatum<\/em><\/del><ins><em>H<\/em><\/ins><ins><em>.<\/em><\/ins> <ins><em>capsulatum<\/em><\/ins>, a dimorphic fungus, is presumed to play a causative role in the development of OHS.<del><sup>1<\/sup><\/del> There are few reports of pathologic and molecular evidence supporting <del>a<\/del> <ins>the<\/ins><ins> <\/ins>direct role <del>for<\/del> <ins>of<\/ins><ins> <\/ins><em>H. capsulatum<\/em> in the development of chorioretinal scars<del>,<\/del> <ins>;<\/ins><ins> <\/ins>however, no serologic confirmation of histoplasmosis infection has been reported.<del><sup>3,4<\/sup><\/del> A h<ins>a<\/ins>ematogenous dissemination of the fungus results in choroidal invasion and subsequent scarring. Additionally, disseminated histoplasmosis<ins> <\/ins>presents with intraretinal infiltrates composed of histoplasma yeast cells <ins>that are<\/ins> easily demonstrable on histology. Extensive study of the affected individuals in Europe and the United States has revealed <ins>the<\/ins> presence of human leukocyte antigen <ins>(HLA<\/ins><del><ins>)<\/ins><\/del>-DR15<ins>)<\/ins><ins>.<\/ins> <del><ins><aq< ins=\"\"><\/aq<><\/ins><\/del><del><ins>1<\/ins><\/del><del><ins>: Please provide the full form of DR&gt;<\/ins><\/del><del>.<\/del><del><sup>5<\/sup><\/del><del> <\/del><del><ins>No full form; it indicates type of HLA<\/ins><\/del>This HLA association suggests <ins>that<\/ins> immune reaction is likely to play a major role during the development of scarring and CNVM. <em>H. capsulatum<\/em><ins> <\/ins>may<ins> <\/ins>induce<del>d<\/del> localized autoimmune reaction in the retina. However, an infection with this fungus is not an absolute requirement for <ins>the<\/ins> development of clinical OHS. Because of this lack of association, there has been a suggestion to rename this clinical syndrome as \u2018multi<ins>\u2013<\/ins>focal choroidopathy\u2019.<\/p>\n<p><del><ins><\/ins><\/del><strong>Epidemiology<\/strong><\/p>\n<p><del><\/del>OHS is most common in the Ohio and Mississippi River valleys of the United States, which are endemic for <em>H. capsulatum<\/em>.<del><sup>6<\/sup><\/del> Up to 70% of the population living in <del>the<\/del> endemic areas react<ins>s<\/ins> positively to the histoplasmin skin testing and 1.5% exhibits <del>the<\/del> typical fundus findings.<ins> <\/ins><del><sup>7<\/sup><\/del>It<ins> <\/ins>can be a blinding disease in its more severe manifestations. There is no gender predilection, although some reports show a higher prevalence in women.<\/p>\n<p><del><ins><\/ins><\/del><strong>Pathobiology<\/strong><\/p>\n<p><del><\/del>OHS belongs to the spectrum of autoimmune diseases triggered by an infectious organism, with <em>H. capsulatum<\/em> being one of several candidate pathogens. It is characterized by a chronic reaction to the immunogenic residua of the <em>H. capsulatum<\/em><em>,<\/em> which acts as a nidus for inflammation. Light microscopy reveals mixed inflammatory cells in <del>the<\/del> choroidal lesions with <ins>the<\/ins><ins> <\/ins>loss of overlying retinal pigment epithelium. There are adhesions between the outer retina and choroidal lesions. The genesis of CNVM in OHS is thought to be caused by <ins>the<\/ins> disruption of Bruch<ins>\u2019<\/ins><del>\u2018<\/del>s membrane at the site of atrophic scar.<\/p>\n<p><del><\/del><strong>Systemic<\/strong> <del><strong>Features<\/strong><\/del><ins><strong>f<\/strong><\/ins><ins><strong>eatures<\/strong><\/ins><\/p>\n<p><del><\/del><del>Mycilia<\/del> <ins>Myc<\/ins><ins>e<\/ins><ins>lia<\/ins> of <del>Histoplasmosis<\/del><ins>h<\/ins><ins>istoplasmos<\/ins><ins>e<\/ins><ins>s<\/ins><ins> <\/ins>are<ins> <\/ins>inhaled and they transform to <ins>the<\/ins> yeast form shortly and infect lungs.<ins> <\/ins>They can produce caseation and enlargement of hilar nodes<ins>,<\/ins> which produce typical<ins> <\/ins>shadows on X-ray. About 90% of cases are benign and do not produce symptoms.<ins> <\/ins><del>In d<\/del><ins>D<\/ins>isseminated<del><ins><aq< ins=\"\"><\/aq<><\/ins><\/del><del><ins>2<\/ins><\/del><del><ins>:<\/ins><\/del> <del><ins>Kindly<\/ins><\/del> <del><ins>&gt;<\/ins><\/del><del><ins>OK<\/ins><\/del> histoplasmosis <del>are<\/del> <ins>is<\/ins><ins> <\/ins>characterized by pyrexia, vomiting and enlargement of liver, spleen<del>,<\/del> and lymph glands.<ins> <\/ins><ins>The<\/ins> <del>Involvement<\/del> <ins>i<\/ins><ins>nvolvement<\/ins> of skin, mouth, gastrointestinal tract and heart may also occur.<\/p>\n<p><del><ins><\/ins><\/del><strong>Ocular<\/strong> <del><strong>Features<\/strong><\/del><ins><strong>f<\/strong><\/ins><ins><strong>eatures<\/strong><\/ins><\/p>\n<p><del><\/del>The clinical findings in OHS include peripapillary atrophy, multiple <del>punched<\/del> <ins>punched<\/ins><ins>\u2013<\/ins>out white atrophic choroidal scars (histo spots)<del>,<\/del> and a macular CNVM, accompanied by the complete absence of a cellular reaction in the anterior chamber or vitreous cavity <ins>[<\/ins><del>(<\/del>Fig. <ins>40.<\/ins>1<ins>(a<\/ins><del>A<\/del>)<ins>]<\/ins>.<del><sup>6<\/sup><\/del> The histo spots are considered to be the earliest stage of the disease<del>,<\/del> and are usually asymptomatic <ins>[<\/ins><del>(<\/del>Fig. <ins>40.<\/ins>1 <ins>(<\/ins><del>B<\/del><ins>b<\/ins>)<ins>]<\/ins>. CNVM will develop in fewer than 5% of individuals with histo spots. <ins>The<\/ins> <del>Clinical<\/del> <ins>c<\/ins><ins>linical<\/ins> presentation of CNVM involves acute or insidious onset <ins>of<\/ins> painless progressive blurring of central vision and metamorphopsia. <ins>The<\/ins> <del>Fundus<\/del> <ins>f<\/ins><ins>undus<\/ins> examination typically shows a yellow-green subretinal discolo<ins>u<\/ins>ration with accumulation of subretinal fluid. In advanced cases<ins>,<\/ins> there is subretinal fibrosis leading to disciform scar formation <del>and<\/del> <ins>that<\/ins><ins> <\/ins>is associated with severe central visual loss.<ins> <\/ins><del><sup>9<\/sup><\/del>The exact time frame between the initial choroidal scarring and CNV<del><ins>&lt;<\/ins><\/del><del><ins>AQ<\/ins><\/del><del><ins>3<\/ins><\/del><del><ins>: Please check if CNV stands for<\/ins><\/del> <del><ins>\u201cchoroidal neovascular<\/ins><\/del><del><ins>ization<\/ins><\/del><del><ins>\u201d<\/ins><\/del><del><ins>and<\/ins><\/del> <del><ins>CNVM is choroidal neovascular membrane<\/ins><\/del> <del><ins>and should be replaced with CNVM<\/ins><\/del><del><ins>&gt;<\/ins><\/del><del><ins>NO<\/ins><\/del> development is difficult to determine given that histo spots are asymptomatic. New histo spots may develop in more than 20% of individuals while they are under observation<del>,<\/del> <ins>;<\/ins><ins> <\/ins>however, only 3.8% progress to CNV. The precipitating factors promoting such progression are not known. Some studies implicate emotional stress and tension headaches as associated event<ins>s<\/ins>.<\/p>\n<p><ins><comp: 40.1=\"\" fig.=\"\" here=\"\" insert=\"\" please=\"\"><\/comp:><\/ins><\/p>\n<p><del><ins><\/ins><\/del><strong>Diagnosis<\/strong><\/p>\n<p><del><\/del>OHS is a clinical diagnosis and relies on <ins>the<\/ins> observation of characteristic fundus lesions in one or both eyes. Intravenous fluorescein angiography (FA) and optical coherence tomography (OCT) can assist in the evaluation of CNVM (Figs<del><ins>.<\/ins><\/del> <ins>40.<\/ins>2 and <ins>40.<\/ins>3). FA assists in identifying areas of CNVM and <ins>in<\/ins> planning photodynamic therapy. OCT is a useful tool for the detection and monitoring of treatment response.<\/p>\n<p><ins><comp: 40.2=\"\" fig.=\"\" here=\"\" insert=\"\" please=\"\"><\/comp:><\/ins><\/p>\n<p><ins><comp: 40.3=\"\" fig.=\"\" here=\"\" insert=\"\" please=\"\"><\/comp:><\/ins><del><sup>10<\/sup><\/del><\/p>\n<p><del><ins><\/ins><\/del><strong>Treatment<\/strong><\/p>\n<p><del><\/del>The optimum<ins> <\/ins>treatment of subfoveal and juxtafoveal<ins> <\/ins>CNVM is <ins>the<\/ins> main focus in OHS. Histo spots are asymptomatic in most cases and require no treatment until a progression of the disease is detected.<del><sup>9-11<\/sup><\/del><\/p>\n<p><del><ins><strong><\/p>\n<h2><\/h2>\n<p><\/strong><\/ins><\/del><strong>Corticosteroids <\/strong><\/p>\n<p><del><\/del>Regimens of systemic corticosteroid therapy were widely used in early studies of ocular histoplasmosis.<ins> <\/ins><del><sup>12<\/sup><\/del>Few clinical studies have evaluated the role of subtenon<del>\u2019s<\/del> and intraocular triamcinolone. The intravitreal steroids demonstrated favo<ins>u<\/ins>rable visual outcomes<ins>;<\/ins> however<ins>,<\/ins> <ins>they<\/ins> are associated with cataract formation or progression and increased intraocular pressure.<del><sup>13<\/sup><\/del><\/p>\n<p><del><ins><strong><\/p>\n<h2><\/h2>\n<p><\/strong><\/ins><\/del><strong>Laser photocoagulation <\/strong><\/p>\n<p><del><\/del>Laser <del>Photocoagulation<\/del> <ins>p<\/ins><ins>hotocoagulation<\/ins> effectively inhibits the progression of OHS-related CNV. In randomized trials, the Macular Photocoagulation Study demonstrated that argon and krypton<ins> <\/ins>laser photocoagulation is effective in treating well-defined, classic extrafoveal, juxtafoveal<del>,<\/del> and peripapillary CNV lesions secondary to OHS.<del><sup>14, 15<\/sup><\/del><ins> <\/ins>Only 12% of treated individuals experienced significant disease progression<del>,<\/del> compared with 42% of <del>the<\/del> control patients.<\/p>\n<p><strong>Surgical therapy<\/strong><\/p>\n<p><del><\/del>The role of submacular surgery for the removal of CNV lesions was evaluated in a multi<ins>\u2013<\/ins>cent<del>e<\/del>r<ins>e<\/ins> randomized clinical trial.<ins> <\/ins><del><sup>16<\/sup><\/del>The study data indicate that surgery may be beneficial to patients with visual acuity worse than 20\/100<del>,<\/del> and subfoveal CNV.<\/p>\n<p><strong>Photodynamic therapy <\/strong><\/p>\n<p><del><\/del>Verteporfin in Ocular Histoplasmosis study enrolled 26 patients prospectively with subfoveal CNV and demonstrated an improvement of visual acuity from baseline as well as an absence of serious adverse events <del>at<\/del> <ins>in<\/ins><ins> <\/ins>2 years.<del><sup>17<\/sup><\/del><\/p>\n<p><strong>Anti-vascular endothelial growth factor<\/strong> <del><strong>(VEGF)<\/strong><\/del> <strong>therapy <\/strong><\/p>\n<p>Several intravitreal<ins> <\/ins>anti-<ins>vascular endothelial growth factor<\/ins> <ins>(<\/ins>VEGF<ins>)<\/ins> treatments are currently being pursued for the treatment of OHS-related CNV. Few retrospective studies have evaluated the role of intravitreal anti-VEGF therapy for CNV associated with OHS. One such study by Ehrlich et al. found that at least 50% of eyes with subfoveal or juxtafoveal CNV experienced <ins>\u2265<\/ins><del>&gt;=3<\/del> <ins>three<\/ins><ins> <\/ins>lines of vision gain and 91.5<del>% to<\/del> <ins>\u2013<\/ins>100% of patients <ins>had<\/ins> improved or <del>had<\/del> stable visual acuity (at 3-<ins>\u2013<\/ins> <del>to<\/del> 12-month follow-up) after <ins>the<\/ins> intravitreal<ins> <\/ins>bevacizumab therapy.<ins> <\/ins><del><sup>18<\/sup><\/del>Similar<ins>l<\/ins>y, <del>the<\/del> results concerning the therapeutic efficacy of ranibizumab are promising. Both treat-and-extend and pro re<ins> <\/ins>nata treatment strategies were effective. A study by Nielsen et al. demonstrated that many eyes<ins> <\/ins>require long-term anti-VEGF therapy to suppress <ins>the<\/ins> choroidal<ins> <\/ins>neovascular activity in OHS.<del><sup>19<\/sup><\/del><\/p>\n<p><del><strong>Suggested reading<\/strong><\/del><\/p>\n<p><del>Smith RE, Ganley JP. An epidemiologic study of presumed ocular histoplasmosis.<\/del> <del><em>Trans Am Acad<\/em><\/del><del><ins> <\/ins><\/del><del><em>Ophthalmol<\/em><\/del><del><ins> <\/ins><\/del><del><em>Otolaryngol<\/em><\/del> <del>1971; 75:994<\/del><del><ins>\u2013<\/ins><\/del><del>-1005.<\/del><\/p>\n<p><del>Gass JDM, Wilkinson CP. Follow-up study of presumed ocular histoplasmosis.<\/del> <del><em>Trans<\/em><\/del><del><ins> <\/ins><\/del><del><em>Am Acad<\/em><\/del><del><ins> <\/ins><\/del><del><em>Ophthalmol<\/em><\/del><del><ins> <\/ins><\/del><del><em>Otolaryngol<\/em><\/del><del><ins> <\/ins><\/del><del>1972; 76:672<\/del><del><ins>\u2013<\/ins><\/del><del>\u2013<\/del><del><ins>6<\/ins><\/del><del>94.<\/del><\/p>\n<p><del>Hawkins BS, Alexander<\/del> <del>J, Schachat AP. Ocular histoplasmosis. In:<\/del> <del><ins><em>Retina<\/em><\/ins><\/del><del><ins><em>.<\/em><\/ins><\/del> <del>Ryan, SJ, Sch<\/del><del>ah<\/del><del>chat, AP, editors.<\/del> <del><em>Retina<\/em><\/del><del>. St. Louis<\/del><del>, MO:<\/del> <del><ins>,<\/ins><\/del><del><ins> <\/ins><\/del><del>Mosby; 2001<\/del><del><ins><aq< ins=\"\"><\/aq<><\/ins><\/del><del><ins>4<\/ins><\/del><del><ins>: Please check the author spelling<\/ins><\/del><del><ins>&gt;<\/ins><\/del><del>.<\/del><\/p>\n<p><del>Oliver A, Ciulla TA, Comer GM. New and classic insights into presumed ocular histoplasmosis syndrome and its treatment.<\/del> <del><em>Curr<\/em><\/del><del><ins> <\/ins><\/del><del><em>Opin<\/em><\/del><del><ins> <\/ins><\/del><del><em>Ophthalmol.<\/em><\/del> <del>2005 Jun;16(3):160<\/del><del><ins>\u2013<\/ins><\/del><del>\u2013<\/del><del><ins>16<\/ins><\/del><del>5.<\/del><\/p>\n<p><del>Prasad AG, Van Gelder RN.<\/del> <del>Presumed ocular histoplasmosis syndrome.<\/del> <del><em>Curr<\/em><\/del><del><ins> <\/ins><\/del><del><em>Opin<\/em><\/del><del><ins> <\/ins><\/del><del><em>Ophthalmol.<\/em><\/del> <del>2005 Dec;16(6):364<\/del><del><ins>\u2013<\/ins><\/del><del>\u2013<\/del><del><ins>36<\/ins><\/del><del>8.<\/del><\/p>\n<p><del>Macular Photocoagulation Study Group. Argon laser photocoagulation for ocular histoplasmosis: results of a randomized trial.<\/del> <del><em>Arch Ophthalmol<\/em><\/del> <del>1983; 101:1347<\/del><del><ins>\u2013<\/ins><\/del><del>\u2013<\/del><del><ins>13<\/ins><\/del><del>57.<\/del><\/p>\n<p><del>Macular Photocoagulation Study Group. Krypton laser photocoagulation for neovascular lesions of ocular histoplasmosis: results of a randomized clinical trial.<\/del> <del><em>Arch Ophthalmol<\/em><\/del> <del>1987; 105:1499<\/del><del><ins>\u2013<\/ins><\/del><del>-1507.<\/del><\/p>\n<p><del>Rosenfeld PJ, Saperstein DA, Bressler NM, et al.<\/del> <del>Photodynamic therapy with verteporfin in ocular histoplasmosis: uncontrolled, open-label 2-year study.<\/del> <del><em>Ophthalmology<\/em><\/del> <del>2004; 111:1725<\/del><del><ins>\u2013<\/ins><\/del><del>\u2013<\/del><del><ins>17<\/ins><\/del><del>33.<\/del><\/p>\n<p><del>Nielsen JS, Fick TA, Saggau DD, Barnes CH.<\/del><del><ins> <\/ins><\/del><del>Intravitreal anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to ocular histoplasmosis syndrome.<\/del> <del><em>Retina.<\/em><\/del> <del>2012 Mar;32(3):468<\/del><del><ins>\u2013<\/ins><\/del><del>\u2013<\/del><del><ins>4<\/ins><\/del><del>72.<\/del><\/p>\n<p><del>Fig.<\/del> <del><ins>ure<\/ins><\/del><del><ins> <\/ins><\/del><del><ins>40.<\/ins><\/del><del>1<\/del> <del>Fundus photo<\/del><del><ins>graph<\/ins><\/del><del>s of<\/del> <del><ins>a<\/ins><\/del> <del>patient with OHS showing peri-papillary atrophy and CNV with subretinal h<\/del><del><ins>a<\/ins><\/del><del>emorrhage in the right eye (A) and macular histo spot in the left eye<\/del><del><ins> <\/ins><\/del><del>(B).<\/del><del><ins>Choroidal neovascularization<\/ins><\/del><del><ins><\/ins><\/del><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Dr Pradeep Venkatesh Histoplasmosis Amol D Kulkarni and Suresh R Chandra Introduction Histoplasmosis is a systemic disease caused by Histoplasma capsulatum.1 Introduction Histoplasmosis is a systemic disease caused by Histoplasma capsulatum.1 It produces intracellular granulomatous inflammation of many organs including eyes, lungs, liver, spleen, etc. Ocular histoplasmosis syndrome (OHS) is characterized by a triad of [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[9869,9870,9889,3953,9940,9799,9939],"class_list":["post-76994","post","type-post","status-publish","format-standard","hentry","tag-au","tag-complete-the-assignment-in-a-page-paper","tag-in-1050-word-essay","tag-need-help-writing-a-masters-thesis","tag-online-class-course-exam-help","tag-research-essay-pro","tag-write-my-essay-homework-due-in-hours"],"_links":{"self":[{"href":"https:\/\/www.colapapers.com\/us\/wp-json\/wp\/v2\/posts\/76994","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.colapapers.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.colapapers.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.colapapers.com\/us\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/www.colapapers.com\/us\/wp-json\/wp\/v2\/comments?post=76994"}],"version-history":[{"count":0,"href":"https:\/\/www.colapapers.com\/us\/wp-json\/wp\/v2\/posts\/76994\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.colapapers.com\/us\/wp-json\/wp\/v2\/media?parent=76994"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.colapapers.com\/us\/wp-json\/wp\/v2\/categories?post=76994"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.colapapers.com\/us\/wp-json\/wp\/v2\/tags?post=76994"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}